Malaria:
A Global Health Emergency
In 2023, over 263 million people worldwide contracted malaria, with nearly 600,000 deaths. Tragically, 95% of all malaria deaths occur in Africa, and 76% of victims are children under five years old. In the Democratic Republic of Congo, malaria continues to be one of the leading causes of child mortality, chronic poverty, and healthcare system strain.
Malaria Cases:
263M
263 million global malaria cases annually - every treatment matters
Malaria Deaths:
597K
Annualy, with 76% being children under 5
Malaria Impact:
700M
additional people could be at risk of malaria due to climate change
Impact:
$12B
Cost per year in healthcare & lost productivity
The Historical Role of Quinine in Malaria Treatment
Derived from the bark of the cinchona tree native to South America, quinine has been used for over 400 years as one of the most effective antimalarial agents in human history. European colonial empires cultivated cinchona across Asia and Africa starting in the 19th century.
Quinine disrupts the malaria parasite’s ability to metabolize hemoglobin inside red blood cells, effectively stopping its replication and enabling the body to clear the infection.
Even with the introduction of newer antimalarial drugs, quinine remains irreplaceable for severe and complicated malaria cases.
Why Quinine Still Matters Today
Despite global progress with Artemisinin Combination Therapies (ACTs), quinine remains essential for:
Severe malaria cases:
IV quinine remains the gold standard for life-threatening, hospitalized malaria.
Emerging drug resistance:
Quinine remains effective where ACT resistance
ACT-intolerant patients:
Especially for pregnant women or individuals who cannot tolerate ACTs.
Supply chain resilience:
Quinine production can be fully localized in Africa, avoiding fragile global ACT dependencies.
WHO Essential Medicines List:
Quinine remains listed as a core medicine.
Pharmakina’s Role
in Malaria Resilience
Full vertical production - from cinchona plantations to finished pharmaceuticals.
Local African production capacity - reducing dependency on foreign imports.
Guaranteed availability even during global supply chain disruptions.
Direct support to national malaria programs and health ministries.
Ethical sourcing tied directly to local farming communities.
Beyond Production:
A Comprehensive Public Health Model
Pharmakina doesn’t only produce medication – we invest in local health capacity:
Centers of Excellence providing free malaria testing and treatment to farming communities.
Healthcare workers embedded in rural zones.
Disease-resistant seedlings securing future raw material supplies.
Women’s empowerment programs supporting gender equality in rural economies.
Local Production, Global Impact.
In a world facing climate change, pandemics, geopolitical shifts, and rising resistance, Pharmakina offers a strategic lifeline for Africa’s malaria response – delivering both life-saving medicines and economic resilience through fully integrated African production.
Combat la Malaria.
not only a slogan, but a mission.